Combating COVID‑19: Identifying a Potential Drug Candidate for Human Testing in 90 Days
Jan 13, 2021 9:00am ‐ Jan 13, 2021 9:15am
Speaker(s):
- Bo Barnhart, PhD, Abcellera Biologics Inc.
Antibodies as Drugs for COVID‑19
Jan 13, 2021 9:00am ‐ Jan 13, 2021 11:40am
Co-Chair(s):
- David P. Humphreys, UCB Pharma, UK
- Esther Breij, Genmab
Rapid Selection, Characterization and Clinical Development of Fully‑Human Antibodies Against Emerging Infectious Diseases
Jan 13, 2021 9:15am ‐ Jan 13, 2021 9:30am
Speaker(s):
- Christos Kyratsous, PhD, Regeneron Pharmaceuticals Inc
Cross‑Neutralization of SARS‑CoV‑2 by a Human Monoclonal SARS‑CoV Antibody
Jan 13, 2021 9:30am ‐ Jan 13, 2021 9:45am
Speaker(s):
- Davide Corti, PhD, Humabs BioMed SA
Neutralizing Antibodies—The Hope for a COVID‑19 Cure
Jan 13, 2021 9:45am ‐ Jan 13, 2021 10:00am
Speaker(s):
- X. Sunney Xie, PhD, Peking University
Human Neutralizing Antibodies Elicited by SARS‑CoV‑2 Infection
Jan 13, 2021 10:25am ‐ Jan 13, 2021 10:40am
Speaker(s):
- Linqi Zhang, PhD, Tsinghua University
When Size Matters: A Broadly Neutralizing Single Domain Antibody to Prevent and Treat COVID 19
Jan 13, 2021 10:40am ‐ Jan 13, 2021 10:55am
Speaker(s):
- Xavier Saelens, PhD, Ghent University
Highly Potent Anti‑SARS‑CoV‑2 Multivalent DARP in Therapeutic Candidates
Jan 13, 2021 10:55am ‐ Jan 13, 2021 11:10am
Speaker(s):
- Michael Stumpp, PhD, Molecular Partners
Therapeutic Effect of Regdanvimab (CT‑P59) in Patients with Mild to Moderate Symptoms of SARS CoV 2 Infection
Jan 13, 2021 11:10am ‐ Jan 13, 2021 11:25am
Speaker(s):
- Michael G. Ison, MD, Northwestern/Celltrion, Inc.